(Q45357826)

13 December 2017

title

Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands (English)

1 reference

13 December 2017

0 references

M J Meijboom

1

1 reference

13 December 2017

M H Rozenbaum

2

1 reference

13 December 2017

A Benedictus

3

1 reference

13 December 2017

W Luytjes

4

1 reference

13 December 2017

M C J Kneyber

5

1 reference

13 December 2017

J C Wilschut

6

1 reference

13 December 2017

E Hak

7

1 reference

13 December 2017

M J Postma

8

1 reference

13 December 2017

language of work or name

English

0 references

publication date

2 May 2012

1 reference

13 December 2017

1 reference

13 December 2017

volume

30

1 reference

13 December 2017

issue

31

1 reference

13 December 2017

page(s)

4691-4700

1 reference

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Rate-difference method proved satisfactory in estimating the influenza burden in primary care visits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Influenza- and respiratory syncytial virus-associated mortality and hospitalisations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Immunity to and frequency of reinfection with respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Modeling epidemics caused by respiratory syncytial virus (RSV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Mortality in children from influenza and respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Impact of wheezing after respiratory syncytial virus infection on health-related quality of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

A review of health utilities across conditions common in paediatric and adult populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

The friction cost method for measuring indirect costs of disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Modelling the epidemiology of infectious diseases for decision analysis: a primer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Respiratory pathogens in respiratory tract illnesses during the first year of life: a birth cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Relative impact of influenza and respiratory syncytial virus in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

The burden of respiratory syncytial virus infection in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Clinical and epidemiologic characteristics of viral infections in a neonatal intensive care unit during a 12-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.072

10.1016/J.VACCINE.2012.04.072

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference